Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study

Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study

Mitotane is the only approved drug for advanced adrenocortical carcinoma (ACC) and no biomarkers are available to predict attainment of therapeutic plasma concentrations and clinical response. Aim of the study was to evaluate the suitability of cytochrome P450(CYP)2W1 and CYP2B6 single nucleotide po...

Full description

Bibliographic Details
Main Authors: Barbara Altieri, Silviu Sbiera, Sabine Herterich, Silvia De Francia, Silvia Della Casa, Anna Calabrese, Alfredo Pontecorvi, Marcus Quinkler, Tina Kienitz, Massimo Mannelli, Letizia Canu, Anna Angelousi, Vasileios Chortis, Matthias Kroiss, Massimo Terzolo, Martin Fassnacht, Cristina L. Ronchi
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cancers
Subjects:
adrenocortical carcinoma
mitotane
cyp2w1
cyp2b6
snp
biomarker
predictive marker
Online Access:https://www.mdpi.com/2072-6694/12/2/359

Internet

https://www.mdpi.com/2072-6694/12/2/359

Similar Items